1. In patients with amyotrophic lateral sclerosis (ALS) and superoxide dismutase 1 (SOD1) mutations, tofersen does not result in significant functional improvement as compared to placebo. 2. In comparison to the placebo, tofersen significantly reduced SOD1 concentrations in the cerebrospinal fluid (CSF) and plasma of persons with faster progressing SOD1 ALS. Evidence Rating Level: 1
Topline data show where sodium phenylbutyrate and taurursodiol fell short
Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK, April 16,…
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited…
Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.
“Every 90 Minutes” has been a tagline that organizations have used for over a decade to describe how often someone dies from ALS in the…
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory…
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
Companies are increasingly using fast-track approval processes to get unproven treatments to patients.
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective…
As diligent taxpayers breathe a sigh of relief that the hassle of filing their tax forms is over for another year, the Internal Revenue Service…
